华夏基金顾鑫峰：当前北交所估值极具吸引力 “永远相信美好的事情即将发生”

Group 1 - The core viewpoint is that the North Exchange (北交所) presents significant investment opportunities, particularly for actively managed public funds, which have demonstrated strong performance compared to the North Index [1][2][3] - The 华夏北交所创新中小企业精选两年定开 fund achieved a net value growth rate of 72.16% in 2025, ranking third in the market, and has a three-year growth rate of 175.64%, making it the top-performing fund in the market [1] - The North Exchange is characterized by a relatively low number of institutional participants, allowing for better value discovery and opportunities for active management to outperform the North Index [2][3] Group 2 - The North Exchange comprises companies that have transitioned from the New Third Board (新三板), with a total of approximately 6065 listed companies, of which 2183 are in the innovation layer [3] - Notable companies listed on the North Exchange include industry leaders such as Jinjie Biological (锦波生物) and Minshida (民士达), indicating the presence of high-quality firms despite the smaller average company size [3][4] - The investment strategy of 华夏基金 focuses on leveraging research capabilities to identify and invest in quality companies within the North Exchange, which is expected to grow as more quality firms list [3][4] Group 3 - The current valuation of the North Exchange is considered attractive, with the North Index's dynamic price-to-earnings ratio at 68 times, compared to other indices like the ChiNext Index at 138 times [7] - Historical trends suggest that small-cap stocks tend to perform well during early economic recovery phases, which aligns with the current market conditions [7][8] - The North Exchange is expected to continue attracting quality companies, with liquidity increasing approximately 30 times over the past three years, enhancing its appeal to institutional investors [8]